MEI Pharma inc – MEIP

April 1, 2018 – June 30, 2018 all-day

MEI Pharma inc – MEIP Has 3 upcoming catalyst in 2Q 2018:

Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 commencement of dosing announced June 14, 2017 – data from first stage due 2Q 2018.

Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)
Phase 1b data to be presented 2Q 2018.

HER2-negative Breast Cancer
Phase 1 data due 2Q 2018.

finviz dynamic chart for  MEIP

Sharing is Caring:

Author: ZitroStocks

Welcome to ZitroStocks, hope you enjoy your visit. You are welcome to ask questions and participate in discussions.

Leave a Reply

Your email address will not be published. Required fields are marked *

One thought on “MEI Pharma inc – MEIP”